APA (7th ed.) Citation

Tevaarwerk, A., Wilding, G., Eickhoff, J., Chappell, R., Sidor, C., Arnott, J., . . . Liu, G. (2012). Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Investigational new drugs, 30(3), 1039-1045. https://doi.org/10.1007/s10637-010-9629-6

Chicago Style (17th ed.) Citation

Tevaarwerk, Amye, George Wilding, Jens Eickhoff, Rick Chappell, Carolyn Sidor, Jamie Arnott, Howard Bailey, William Schelman, and Glenn Liu. "Phase I Study of Continuous MKC-1 in Patients with Advanced or Metastatic Solid Malignancies Using the Modified Time-to-Event Continual Reassessment Method (TITE-CRM) Dose Escalation Design." Investigational New Drugs 30, no. 3 (2012): 1039-1045. https://doi.org/10.1007/s10637-010-9629-6.

MLA (9th ed.) Citation

Tevaarwerk, Amye, et al. "Phase I Study of Continuous MKC-1 in Patients with Advanced or Metastatic Solid Malignancies Using the Modified Time-to-Event Continual Reassessment Method (TITE-CRM) Dose Escalation Design." Investigational New Drugs, vol. 30, no. 3, 2012, pp. 1039-1045, https://doi.org/10.1007/s10637-010-9629-6.